Recent advances and future therapy development for Alzheimer’s disease and related disorders

作     者：Megan Hong Gal Bitan Megan Hong;Gal Bitan

作者机构：Department of NeurologyDavid Geffen School of MedicineUniversity of California Los AngelesLos AngelesCAUSA Department of Chemistry and BiochemistryUniversity of California Los AngelesLos AngelesCAUSA Molecular Biology InstituteUniversity of California Los AngelesLos AngelesCAUSA Brain Research InstituteUniversity of CaliforniaLos AngelesCAUSA 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2024年第19卷第9期

页      面：1877-1878页

核心收录：

学科分类：1002[医学-临床医学] 100203[医学-老年医学] 10[医学] 

基　　金：supported by NIH grants RF1NS126406 and R21NS130326 by a generous gift from the Binder Foundation (to GB) 

主　　题：Alzheimer globally patients 

摘      要：Over 55 million people globally live with Alzheimer’s disease(AD)or related dementias(ADRD)and the number is expected to double every twenty *** i l recent l y,onl y symptomatic treatments were available to patients with AD,including acetylcholine esterase inhibitors,of which the last one,galantamine,was approved by the US Food and Drug Administration(FDA)in 2001.